Hematology/Oncology News

In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.

A universal screening and opt-out referral strategy may reduce disparities in tobacco treatment access and increase use of smoking cessation services by people with cancer, according to results of a qualitative improvement study.

Editor’s note: This is the fourth in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

The addition of nivolumab to low-dose tivozanib did not improve PFS for patients with advanced renal cell carcinoma, according to data from the agent’s manufacturer.

PHILADELPHIA — In this video, Michael Fisher, MD, highlights a keynote presentation given by Charles Limoli, PhD, at the International Symposium on Pediatric Neuro-Oncology.

Treatment with Dupixent led to histologic remission at week 16 among a greater percentage of pediatric patients with eosinophilic esophagitis refractory to proton-pump inhibitor therapy compared with placebo, according to study results.

Obecabtagene autoleucel conferred durable benefit to certain patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of the phase 1B/phase 2 FLEIX study presented at ASCO Annual Meeting.

ORLANDO, Fla. — Malignancies and lung involvement are the two key manifestations of dermatomyositis that require vigilance, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

A longitudinal cohort study has yielded new insights into risks for and long-term effects of cisplatin-related hearing loss.

Rates of next-generation sequencing have increased for individuals with metastatic prostate cancer or advanced urothelial carcinoma over the past several years, but more than half of these individuals still do not undergo testing.